Hantavirus Infection

B1 Crossref Works API · 2026-06-26

Hantavirus infections remain rare but clinically significant zoonotic diseases associated with high morbidity and mortality. Despite ongoing research, no FDA‑approved pharmacotherapies exist, and management is largely supportive. This review summarizes current evidence on hantavirus pathophysiology, clinical presentation, diagnostic strategies, and investigational treatments, with a focus on the potential role of ribavirin and other emerging therapies. Although early studies suggested that ribavirin may reduce mortality when administered within the first 5 days of symptom onset, subsequent tri

Read at source (Crossref Works API) →

HORIZON metadata

Open the live outbreak map →